RxSight (RXST) to Release Earnings on Wednesday

RxSight (NASDAQ:RXST) will likely be posting its Q4 2025 results after the market closes on Wednesday, February 25th. Analysts expect RxSight to post earnings of ($0.25) per share and revenue of $32.6020 million for the quarter. Parties may review the information on the company’s upcoming Q4 2025 earning report for the latest details on the call scheduled for Wednesday, February 25, 2026 at 4:30 PM ET.

RxSight Price Performance

RxSight stock opened at $8.61 on Wednesday. The stock has a fifty day moving average price of $10.01 and a two-hundred day moving average price of $9.46. RxSight has a 52-week low of $6.32 and a 52-week high of $31.78. The firm has a market capitalization of $354.04 million, a P/E ratio of -9.78 and a beta of 1.14.

Analysts Set New Price Targets

RXST has been the topic of several research analyst reports. Wolfe Research raised shares of RxSight to an “outperform” rating in a research note on Friday, January 30th. UBS Group reissued a “neutral” rating on shares of RxSight in a report on Monday, January 12th. Wells Fargo & Company raised their price target on RxSight from $9.00 to $10.00 and gave the company an “equal weight” rating in a report on Thursday, November 6th. William Blair started coverage on RxSight in a research note on Friday, January 30th. They issued a “market perform” rating on the stock. Finally, JPMorgan Chase & Co. increased their target price on RxSight from $8.00 to $9.00 and gave the stock an “underweight” rating in a report on Thursday, November 6th. Two equities research analysts have rated the stock with a Buy rating, ten have issued a Hold rating and three have given a Sell rating to the stock. According to MarketBeat.com, RxSight has a consensus rating of “Reduce” and a consensus price target of $9.78.

Hedge Funds Weigh In On RxSight

Hedge funds and other institutional investors have recently bought and sold shares of the business. Raymond James Financial Inc. bought a new position in shares of RxSight in the 2nd quarter worth $28,000. Caitong International Asset Management Co. Ltd increased its holdings in RxSight by 440.7% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 3,758 shares of the company’s stock valued at $39,000 after purchasing an additional 3,063 shares during the last quarter. Larson Financial Group LLC lifted its stake in RxSight by 110.5% in the third quarter. Larson Financial Group LLC now owns 3,979 shares of the company’s stock valued at $36,000 after buying an additional 2,089 shares during the period. Tower Research Capital LLC TRC boosted its holdings in RxSight by 156.2% during the second quarter. Tower Research Capital LLC TRC now owns 5,574 shares of the company’s stock worth $72,000 after buying an additional 3,398 shares during the last quarter. Finally, Russell Investments Group Ltd. grew its position in shares of RxSight by 112.3% during the 2nd quarter. Russell Investments Group Ltd. now owns 8,684 shares of the company’s stock worth $113,000 after buying an additional 4,593 shares during the period. 78.78% of the stock is owned by institutional investors.

RxSight Company Profile

RxSight, Inc is a medical technology company focused on the development and commercialization of advanced intraocular lens (IOL) systems for patients undergoing cataract surgery and lens replacement procedures. The company’s flagship product, the Light Adjustable Lens (LAL), is designed to provide customized vision correction by allowing non‐invasive post‐operative adjustments. Using ultraviolet light, surgeons can fine‐tune the lens power after implantation to achieve optimal visual outcomes, reducing reliance on glasses or contact lenses and enhancing patient satisfaction.

Founded in 2011 and headquartered in Aliso Viejo, California, RxSight has pursued regulatory clearances and market access across multiple regions.